⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2024

[Preliminary clinical use of hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab in the treatment of unresectable intrahepatic cholangiocarcinoma].

B J Zhou Weishu Wang Yufeng Yin Jun Yang Xiaoli Zhu Caifang Ni

View at Publisher

Ask AI

Bookmark

Share

Abstract

To evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib and tislelizumab in the treatment of unresectable intrahepatic cholangiocarcinoma (ICC).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhou et al. (2024) studied this question.

synapsesocial.com/papers/68e5e0e0b6db643587574a96 https://doi.org/10.3760/cma.j.cn112138-20231102-00287

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma.2024
2Hepatic artery infusion chemotherapy (HAIC) combined with tislelizumab and lenvatinib for initial unresectable hepatocellular carcinoma (HCC) with portal vein tumor thrombus: A prospective, single-arm phase II trial.2024 · 4 citations
3Efficacy and safety of tislelizumab and apatinib combined with hepatic arterial infusion chemotherapy for advanced intrahepatic cholangiocarcinoma: A single-arm, phase 2 study.Early-Phase Clinical Trial · 2026
4Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma2024 · 18 citations
5First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma2024 · 13 citations

More related papers

First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma: a real-world study2024
Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein‐1 inhibitors: A promising treatment approach for high‐burden hepatocellular carcinoma2024
Hepatic Arterial Infusion Chemotherapy Plus Systemic Chemotherapy, Lenvatinib and PD-(L)1 Inhibitors Versus Systemic Chemotherapy Plus PD-(L)1 Inhibitors in Advanced Intrahepatic Cholangiocarcinoma.2026